

Capital Raising & Corporate Presentation

November 2022

empowering
advanced concussion
management

HIT·IQ



IMPORTANT NOTICE AND DISCLAIMER

This presentation has been prepared by HITIQ Limited (HIQ) and is provided for general information purposes only. No party other than HITIQ has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. HITIQ makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. HITIQ and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of HITIQ. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by HITIQ or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Capital Raising Overview

Renounceable
Rights Issue Offer





Corporate Summary.

Capital Structure (27 October 2022)

ASX Code	HIQ
Share Price	\$0.041
Shares on Issue	132.4 M
Unlisted Options	28.2 M
Market Capitalisation	\$5.4M
Cash in bank (30 Sep 2022)	\$1.4 M

Shareholders

Top 20 Shareholders 36%



Renounceable Rights Issue Offer.

KEY DETAILS OF THE OFFER

Offer to Eligible Shareholders	<ul style="list-style-type: none">> 8 New Shares for every 5 Shares held at the Record Date at the Issue Price plus;> 1 Option for every 1 New Share subscribed under the Offer.> Option means a New Option to purchase a Share with an exercise price of \$0.04 and an Expiry Date of 9th December 2023;> a Top-Up Facility for Shareholders who subscribe for their full Entitlement
Issue Price per New Share	\$0.03 or 3 cents per New Share payable in full on Application
Maximum proceeds from the Offer (excluding costs associated with the Offer)	\$6,356,113
Existing Shares as at date of the Offer	132,419,018
Maximum number of New Shares issued under the Offer	211,870,429
Total issued Shares following completion of the Offer	344,289,447



Use of Funds.

The proposed capital raise will:

- ▶ Progress commercialisation activities within the consumer market.
- ▶ Assist in leveraging early adopters in elite market into broader commercial success
- ▶ Fund important further clinical & technical development work on HITIQ’s medical technology products; and
- ▶ Investigate IP expansion possibilities

Sales & marketing of consumer facing product suite	\$0.70m
Further development technology platform including virtual reality pre-clinical activities	\$1.9m
Working capital	\$1.1m
Possible IP Acquisition Opportunities	\$2.35m
Costs of the offer	\$0.30m
Total	\$6.35m



Timetable.

Indicative Rights Issue Timetable ¹ Event	Date
Rights Issue announcement and company resumes trading	Tuesday, 1 November 2022
Record Date	Thursday, 10 November 2022
Dispatch of Prospectus and Rights Issue Offer opens	Monday, 14 November 2022
Rights trading ends at close of trading	Friday, 25 November 2022
Closing of Rights Issue Offer	5.00pm Friday, 2 December 2022
Announcement of results of the Offer	Wednesday, 7 December 2022
Allotment and issue of New Shares under Rights Issue Offer	Friday, 9 December 2022
Expected normal trading of New Shares under Rights Issue Offer	Tuesday, 13 December 2022

1. Dates / times are indicative and subject to change. All times / dates are in reference to Australian Eastern Standard Time



Compelling opportunity with large potential upside.

- ▶ **Global technology-led concussion management opportunity**
- ▶ **Disruptive technology with multi billion-dollar addressable markets (+\$8b)**
- ▶ **Significant brain impact databank asset across major sporting codes**
- ▶ **Targeting growth in existing revenues within Sports segment**
- ▶ **Proprietary, versatile, purpose-built platform**
- ▶ **Entry into an exciting & emerging virtual reality segment, allowing expansion into Allied Health**
- ▶ **Supported by a World class Scientific & Medical Advisory Council (SMAC)**



Large unmet market need; There is no widely implemented solution to solve for better managing concussion-brain injury in sports.

- ▶ An athlete who sustains a concussion is 4-6 times more likely to sustain a second concussion.
- ▶ Effects of concussion are cumulative in athletes who return to play prior to complete recovery.
- ▶ Cumulative exposure to sub-concussive impacts may have negative long term brain health implications
- ▶ Brain Injury Management response & pathway not well known in the community

Concussion **lawsuits** challenging duty of care of sporting codes

10-20% of all contact sport athletes sustain concussions annually.

17% of parents are confident in correctly managing a potential concussion incident.

40% of parents who don't allow their children to play contact sports is because of **concussion concerns**


1.6 to 3.8m reported sport related concussions in the US annually.

50% of concussions go unreported or undetected.



Fundamental failure points across current protocols lead to poor health outcomes & governance risk exposure.

Athlete Journey



Key Takeaways

Observational Methods Ineffective

Impossible to Identify, Track & Quantify impact exposure via the naked eye.

Inadequate Assessment & Diagnostic Protocols

Current tests lack sensitivity, specificity & athlete engagement.

Long Term Brain Health Issues Emerging


Unresolved acute & chronic exposure compound on-going risk.



VISION

What We Aim To Achieve

EMPOWER **CLINICIANS**, PROTECT **ATHLETES** &
SERVE **LEAGUES** AROUND THE GLOBE WITH
QUALITY DATA TO REFORM THE CONCUSSION
CARE MODEL.



End-to-end data strategy across care journey is underpinning our competitive moat.

Our brain health platform aims to provide **a holistic technology led ecosystem** that supports the identification, monitoring and rehabilitation of sport-related brain injury (concussion & sub concussion).

The mission is to:

1. Eliminate risk of **acute concussions** being undetected & undiagnosed;
2. Ensure the monitoring of potential longer-term effects related to the accumulation of **sub concussive impacts**.




Convergence of concerns around **duty of care, well being & litigation** is rapidly growing awareness & adoption of new technologies.




World's first commercial end-to-end brain injury management platform.

Three pillar strategy driving our end-to-end vision



One technology platform provides opportunity to target all components of end-to-end journey.

Nexus



Surveillance System

Wearable sensor technology embedded into mouth guards which tracks, records & alerts both acute & chronic head impact loads.

STATUS: **COMMERCIAL**

CSX



Digital Assessment Tool

Leading concussion assessment application offering a centralised digital assessment record in line with standardised assessment protocols.

STATUS: **COMMERCIAL**

CoVR



Virtual Reality Diagnostic Aid

Immersive, sensitive & comprehensive test protocol within virtual reality environment to define both acute and chronic cognitive impairment.

STATUS: **VALIDATING**


reCoVR



Virtual Reality Brain Injury Recovery

Future development centered around maintaining brain health through VR directed training & recovery program

STATUS: **PLANNING**



Global leadership in impact sensor technology.

Purpose built wearable technology delivering validated brain impact data through sophisticated algorithms and machine learning methodologies.

Only form factor able to validly collect head impact data due to positioning of sensors in rigid form near the brain.

Thousands of athletes instrumented, and individual longitudinal databanks established.

+3k Units in Elite Market Globally


+25m Data Points & Growing

98% System Accuracy






Building a significant asset base of brain impact data across a well-developed data capture program.





Increasing Data capability key area for future development.



HITIQ data shows:

Athletes playing contact sports on average are experiencing up to 30 brain impacts per game or up to **~750 per season.**

What does this mean?



HITIQ databank is now approaching scale to begin developing **predictive capabilities**





Strong Consumer Go-to-Market Strategic Partnerships for Nexus.



Partnership to deliver technology into grass roots through the largest health insurer in Australasia. Providing subsidy to customers through existing health insurance policies.


- ▶ **257 dental clinics within Australia**
- ▶ **4.5m members**
- ▶ **International growth prospects within BUPA network**



Entered into MoU Shock Doctor, Inc. is the world-leader in sports mouthguards across the consumer category. Provides expansion pathway into retail segment of consumer market.

- ▶ **Global leader in manufacturing capabilities**
- ▶ **Access to over 20,000 global retail locations**
- ▶ **Worn by hundreds of professional & college athletes**





Electronic record for standardized concussion assessment protocols.

Vast databank of baseline and Head Impact Assessments (HIA) performed.

Thousands of **brains under managements** through CSX platform.


Critical compliance and digital record keeping tool for clinicians.

+60 Competitions & Leagues

+800 Customers Globally

+125,000 Assessments Performed





Strong adoption from Elite Market to help launch CSX community platform early 2023.

Current concussion management protocols in the community face the following challenges:

- ▶ The standard of care provided by general practitioners is **extremely varied** and mostly inept.
 - ▶ Time **delays** in seeing a practitioner can be days
- ▶ Four in five parents (**79%**) report that sports clubs need more information about how to manage potential concussion incidents.
- ▶ Only one in six parents (**17%**) strongly agree that they are confident in their ability to correctly manage a potential concussion incident.





Assessing the brain's cognitive performance with virtual reality.

Technology Background
& Path to Market





Entry into an emerging technology sector, opening access to a lucrative diagnostic market.

The CoVR test protocol utilises an array of proprietary mini games designed to ensure a robust assessment of the various cognitive abilities that can be adversely affected by concussion.

The mini game tests have been developed to assess each cognitive domain in isolation, which though a validation process has been demonstrated.

Pre-clinical trial phase commencing shortly **led by UCLA**, that will ultimately lead to a clinical trial.

Pursuing a **Class II** Medical Device classification





New approach for cognitive assessment.

Migrates traditional paper and subjective evaluations to a more sophisticated level and enhanced sensitivity.

The system provides robust assessments that can assess cognitive skills in a more standardised, objective & reproducible manner through;

- ▶ **Immersive experience**
- ▶ **Gamified assessments**
- ▶ **Enhanced engagement and effort**



The system aims to assist in the assessment & diagnosis of **acute concussion** injury as well as monitoring any long-term impairments as a result of **chronic exposure to brain impacts**.





Scientific Rational Designed to identify & define brain injury.

The CoVR test protocol utilises an array of proprietary mini games designed to ensure a robust assessment of the various cognitive abilities that can be adversely affected by concussion.

A circular icon containing the number "01" in a bold, sans-serif font.

Comprehensive Coverage

Concussions and longer-term impairment can present in a variety of ways across any domain, hence the importance for a comprehensive test suite.

A circular icon containing the number "02" in a bold, sans-serif font.

Cognitive Loading

Many symptoms of impairment only present upon a progressive “loading” of tasks. This requires assessment in longer form.

A circular icon containing the number "03" in a bold, sans-serif font.

Unique Domains


CoVR has the ability to separate cognitive domains entirely, helping to provide precise information on the impaired domain.





Comprehensive Testing Across Multiple Domains.


	Cognitive Domain
Test 1	Verbal Learning & Immediate Recognition Memory
Test 2	Processing Speed
Test 3	Visual Motor Speed
Test 4	Complex Processing Speed & Inhibitory Control
Test 5	Complex Processing Speed, Inhibitory Control & Mental Flexibility
Test 6	Complex processing speed, executive function & planning.
Test 7	Visual Working Memory







Regulatory Overview.

- ▶ 510K required for **Class II Medical Device** classification as a Concussion Diagnostic Aid
- ▶ FDA **Q-Sub** has been submitted and a predicate device have been identified
- ▶ Ethics **approved** at each site for Studies 1, 2, 3 & 4
- ▶ Commencing **pre-clinical research** Studies 1-4 during Q2 FY'23
- ▶ **Clinical trial** testing indicatively scheduled for Q1 FY'24
- ▶ Initial indication targeting **acute concussion diagnosis**
- ▶ **Secondary Indication** will target definition of chronic brain exposure on medium term roadmap





Clinical Validation Pathway.





A factor analysis compresses game outcomes into singular variables resulting in five factors.

These factors represent specific cognitive domains - Inhibition, Reaction Speed, Perceptual Motor, Visual Working Memory and Memory. The blue boxes show that the factors are not correlated.





This demonstrates that CoVR successfully discriminates between the cognitive domains.

The correlation graph demonstrates a high correlation within CoVR games, demonstrated by the triangles along the diagonal line.



This graph indicates that the CoVR tests are successfully measuring the specific cognitive domains they were designed for.

Results - Validation Testing.





Pre Clinical Testing Locations.

Pre clinical testing is underway at a number of sites in Australia and North America following successful ethics applications. Upon completion of successful pre clinical testing, the Study 5 Clinical trial will commence.



University of California, Los Angeles – USA



University of Nevada, Reno

University of Nevada, Reno - USA



Brigham Young University - USA




University of Newcastle - AUS






Pre-Clinical Trial Studies.





Clinical Trial

Study 5 – Internal Validity v2.




PARTICIPANTS

Two cohorts will complete the CoVR Protocol;

Concussed; **n =100**

Healthy control; **n = 100**

*minimum numbers



LOCATION

Multi-site enrolment program.

Locations recruited early 2023



DURATION

Expected **6 months** with preliminary findings released following collection of the concussed population.



DESIGN

Concussed athletes will be assessed between **24 and 72 hours** of sustaining the concussion. The healthy control participants will be assessed at baseline.

* The trial design is subject to approval by a Human Research Ethics Committee (HREC). Trial design documentation will be submitted to HRECs in Q3 FY23.





Market Opportunities

Following Class II Medical Device Classification, a number of CPT codes would be available for use with CoVR.

96132 Neuropsychological testing evaluation. Includes integration of patient data, interpretation of results and clinical data, clinical decision making, treatment planning and report by a healthcare professional.

96136 For the first 30 minutes of test administration and scoring performed by a physician or other qualified health professional.

96138 For the first 30 minutes of test administration performed by a technician

The global Virtual Reality (VR) in healthcare market is projected to grow from \$628.0 million in 2022 to **\$6.20 billion by 2029**, at a **CAGR of 38.7%***

*<https://www.fortunebusinessinsights.com/industry-reports/virtual-reality-vr-in-healthcare-market-101679>



Trusted by the largest sporting codes & leagues across the globe to deliver highly valuable data.



"Football is an evolving sport, I am pleased that HITIQ's technology is improving our ability to quantify our athletes head impacts"



BRETT MORTENSEN

Brigham Young University Rehab Coordinator

"I want all my head impacts monitored and I believe all players should be wearing a HITIQ mouthguard"



JARRYN GEARY

St Kilda Captain, AFL

"I'm very happy with the size and fit. I want my head impacts monitored and I think all players should be wearing a HITIQ mouthguard"



CURTIS SIRONEN

Manly Sea Eagles, NRL

"We have tackle, ruck and maul counts, but this doesn't give us the insight we want as to the intensity of these events. Data from the HITIQ Nexus system aims to help my team quantify players impact load. We can then adjust training and recovery stimulus/thresholds accordingly, which is absolute gold".



CRUSADERS

GARETH DUDER

Crusaders Head of Performance



Well positioned for growth across multiple sectors.

Technology Suite Offering

Robust R&D phase has delivered a scientifically validated technology CSX acquisition helps achieve symbiotic technology suite.

Consumer Growth Pathways Established

Established partner portfolio to facilitate strong entry into consumer segment within local and international markets. USA consumer opportunity through potential of Shock Doctor partnership.

Strong Customer Base In Elite Market


Early customer and trial partners set strong foundation for continued growth in elite segment.
Data captured to date establishes HITIQ in leadership position

Blue Sky

Virtual Reality clinical trial roadmap provides access to lucrative healthcare market & dramatically grows the TAM.



Strong building blocks of IP Portfolio.



We're targeting a growing worldwide concussion-brain injury market including elite and community sport, & allied health segments.

HITIQ has established a data subscription model for its integrated hardware & software solutions.

HITIQ **retains rights to all data** collected for any project and/or commercial agreement through our products.

		Accounts	Athletes	Nexus	CSX	CoVR
Tier 1	ELITE SPORT	10k	500k	\$310m	\$28m	\$100m
	CONSUMER	110k	11m	\$3.6Bn	\$77m	
	ALLIED HEALTH	300k			\$1.5Bn	\$3Bn
Tier 2	MILITARY					
	RESEARCH					
ADDRESSABLE MARKET				\$3.91Bn	\$1.61Bn	\$3.1Bn

*Size of market reflects management data



Near term news flow pipeline...

- ▶ NEXUS deal flow from various projects crystalising
- ▶ Expansion of consumer go-to-market distribution infrastructure
- ▶ Progress Shock Doctor relationship & entry into US consumer segment
- ▶ Extension of CSX technology into community
- ▶ Pre-clinical trial study results
- ▶ Recruitment of Clinical trial sites



BOARD OF DIRECTORS



Otto Buttula
Non-Executive Chairman



Aidan Clarke
Non-Executive Director



Glenn Smith
Non-Executive Director



Phil Carulli
Non-Executive Director

Extensive experience & success in investment research, funds management & information technology. Held directorships in several public companies

Previously co-founder of 2XU with vast sales distribution networks globally, particularly in USA.

Experienced investor and director, success growing customer-centric businesses at all stages of the growth cycle

Chartered Accountant specializing in startup capital raising, corporate compliance & governance.

MANAGEMENT



Mike Vegar
Founder & Managing Director



David Erikson
Chief Technology Officer



Damien Hawes
Chief Commercial Officer



Tom Laudensch
Chief Operating Officer

Decade in elite sports across variety of roles, delivering sport science services. Led HITIQ growth from inception.

20+ years exp across multi-nationals & startups previously Previously (AMD, Intel).

12+ years technology sales & strategy leadership roles. Previously (ASX:CAT).

Proven ability delivering technology to elite sports market Previously (ASX:CAT).

SCIENTIFIC & MEDICAL ADVISORY COUNCIL



Honorary Associate Professor
Andrew Gardner
Council Chair (Australia)



Emeritus Professor
Jeffrey V. Rosenfeld
AC OBE
Council Member (Australia)



Professor
Carolyn Emery
Council Member (Canada)



Doctor
Robby Sikka
Council Member (United States)



Assistant Professor
Doug Terry
Council Member (United States)



Doctor
Joshua Goldman
Council Member (United States)



HIT·IQ

empowering
advanced concussion
management

- ENDS -

Authorised for release by the Board of Directors

Mike Vegar
CEO & MD
HITIQ Limited
investors@hitiq.com

Elvis Jurcevic
Investor Relations
+61 408 268 271
ej@hitiq.com

